Aardvark Therapeutics Inc. (AARD)
AARD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1774857/000119312526119770/0001193125-26-119770-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AARD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0001774857 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$57.6M |
| Operating income | -$62.7M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $47.1M |
| Total assets | $117.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-13 |
| Cash and burn | $60.3M cash; operating cash flow -$16.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 21,891,271 (2026-11-02); 21,773,272 a year earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-03 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., San Diego, California, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $145K, sold $395K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$19.2M | -$13.5M | $60.3M | No debt tags | $0 | 10-Q 2026-11-13 |
| Q2 2026 2026-06-30 | $0 | -$14.4M | -$17.6M | $73.8M | No debt tags | $0 | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $0 | -$21.6M | -$18.9M | $62.4M | No debt tags | $0 | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $0 | -$17.6M | -$16.8M | $47.1M | No debt tags | $0 | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $0 | -$16.3M | -$16.1M | $39.3M | No debt tags | $717K | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $0 | -$14.4M | -$9.8M | $26.0M | No debt tags | $1.7M | 10-Q 2025-08-13 |
| Q1 2025 2025-03-31 | $0 | -$9.3M | -$11.4M | $26.5M | No debt tags | $2.3M | 10-Q 2025-05-14 |
| Q4 2024 2024-12-31 | $717K | -$8.8M | -$7.7M | $61.6M | No debt tags | $2.4M | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-03 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-07-10 |
Source: SEC EDGAR submissions feed, 120 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +13.7% |
| 1 month | -67.1% |
| 3 months | -79.3% |
| Year to date | -89.9% |
| 1 year | -87.8% |
| From 52-week high | -91.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RMTI | Rockwell Medical Inc. | $6.76 | -4.38% | $26.9M |
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
| BCTX | BriaCell Therapeutics Corp. Common Shares | $3.30 | -2.65% | $28.8M |
| SCYX | SCYNEXIS Inc. | $2.91 | -9.35% | $29.0M |
| ACET | Adicet Bio Inc. | $2.75 | -1.08% | $25.7M |
| LITS | Lite Strategy Inc. | $0.8565 | +1.16% | $25.6M |
| PMN | ProMIS Neurosciences Inc. Common Shares (ON) | $3.31 | +0.61% | $29.8M |
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier